News headlines about BioLife Solutions (NASDAQ:BLFS) have been trending positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioLife Solutions earned a media sentiment score of 0.35 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 45.5175960987432 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

BioLife Solutions (NASDAQ:BLFS) traded up $0.14 during trading on Tuesday, hitting $4.99. The stock had a trading volume of 30,100 shares, compared to its average volume of 64,288. The company has a market capitalization of $68.00, a price-to-earnings ratio of -11.88 and a beta of 0.32. BioLife Solutions has a twelve month low of $1.91 and a twelve month high of $7.53.

Separately, Maxim Group restated a “buy” rating and set a $7.00 target price on shares of BioLife Solutions in a report on Thursday, October 26th.

In other news, CEO Michael Rice sold 12,540 shares of BioLife Solutions stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $5.57, for a total value of $69,847.80. Following the transaction, the chief executive officer now directly owns 152,057 shares in the company, valued at $846,957.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 36.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://theolympiareport.com/2018/02/13/positive-media-coverage-somewhat-unlikely-to-impact-biolife-solutions-blfs-share-price.html.

About BioLife Solutions

BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.